Zeeshan Mansuri, MD, MPH

a:1:{i:0;s:57:"Yale New Haven School of Medicine, New Haven, Connecticut";}

PCC
Commentary

January 20, 2022

Patients with psychiatric disorders may be at greater risk of experiencing adverse outcomes from COVID-19. Read on to find out more.
, ,
PCC
Brief Report

October 28, 2021

In this report, the authors review the potential drug-to-drug interactions and safety of using benzodiazepines with COVID-19 antiviral drugs.
, , , et al
PCC
Case Report

March 25, 2021

Here, the authors present a unique presentation of an adolescent girl with a history of bulimia nervosa with multiple chronic episodes of voluntary purging, which were immediately followed by...
, , , et al
PCC
Letter to the Editor

February 18, 2021

In this letter to the editor, the authors reply to Kow and Hasan.
, , , et al
PCC
Commentary

July 2, 2020

In this commentary, the authors discuss the potential interactions of opioid use disorder treatments with novel COVID-19 medications.
, , , et al
PCC
Commentary

June 18, 2020

In this commentary, the authors discuss the potential interactions of ritonavir/lopinavir with psychiatric medications in the context of COVID-19.
, , , et al
PCC
Commentary

May 28, 2020

The FDA has approved remdesivir for severe COVID-19 in children and adults. This commentary reviews potential interactions of remdesivir with psychotropic medications.
, , , et al
PCC
Letter to the Editor

December 26, 2019

The authors of this letter to the editor comment on a previously published report on pimavanserin in The Primary Care Companion for CNS Disorders.
, , , et al

Watch the New PsychCase360

Explore two real-world schizophrenia cases

Subscribe to read
more articles

Subscribe